Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye

Archives of Ophthalmology

Volumn 131, Issue 1, 2013, Pages 24-28

  Sambursky, Robert ^a   Davitt III, William F ^g   Latkany, Robert ^b   Tauber, Shachar ^c   Starr, Christopher ^d   Friedberg, Murray ^a   Dirks, Monte S ^e   McDonald, Marguerite ^f  

^a Manatee Sarasota Eye Clinic and Laser Center   (United States)

^b Physician Eyecare of NY   (United States)

^c St John's Hospital   (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^e Black Hills Regional Eye Institute   (United States)

^f OPHTHALMIC CONSULTANTS OF LONG ISLAND   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; FLUORESCEIN;

ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CORNEAL FLUORESCEIN STAINING; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DRY EYE; EYE INFLAMMATION; FLUORESCEIN TEAR BREAK UP TIME; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OCULAR SURFACE DISEASE INDEX; OUTCOME ASSESSMENT; POINT OF CARE TESTING; PREDICTIVE VALUE; PRIORITY JOURNAL; SCHIRMER TEST; SENSITIVITY AND SPECIFICITY; STAINING; ADOLESCENT; ADULT; AGED; CHEMISTRY; CONJUNCTIVA; CONTROLLED CLINICAL TRIAL; CORNEA; DOUBLE BLIND PROCEDURE; ENZYMOLOGY; FEMALE; FLUOROPHOTOMETRY; HOSPITAL INFORMATION SYSTEM; KERATOCONJUNCTIVITIS SICCA; LABORATORY DIAGNOSIS; LACRIMAL FLUID; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SJOEGREN SYNDROME; CLINICAL ASSESSMENT; CLINICAL FEATURE; EYE EXAMINATION; OCULAR SURFACE DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CONJUNCTIVA; CORNEA; DOUBLE-BLIND METHOD; FALSE POSITIVE REACTIONS; FEMALE; FLUORESCEIN; FLUOROPHOTOMETRY; HUMANS; IMMUNOASSAY; KERATOCONJUNCTIVITIS SICCA; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; POINT-OF-CARE SYSTEMS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SJOGREN'S SYNDROME; TEARS; YOUNG ADULT;

MLCS; MLOWN;

EID: 84872303661     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2013.561     Document Type: Article

References (41)

1. 2007 Report of the International Dry Eye Workshop (DEWS). Ocul Surf. 2007;5:65-204.
2. Chotikavanich S, De Paiva CS, Li Q, et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest Ophthalmol Vis Sci. 2009;50(7):3203-3209.
3. Behrens A, Doyle JJ, Stern L, et al Dysfunctional Tear Syndrome Study Group. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea. 2006;25(8):900-907. (Pubitemid 44763848)
4. McCollum CJ, Foulks GN, Bodner B, et al. Rapid assay of lactoferrin in keratoconjunctivitis sicca. Cornea. 1994;13(6):505-508. (Pubitemid 24332725)
5. Pflugfelder SC, Jones D, Ji Z, Afonso A, Monroy D. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. Curr Eye Res. 1999;19(3):201-211. (Pubitemid 29500267)
6. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and antiinflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42(10):2283-2292. (Pubitemid 32848857)
7. Afonso AA, Sobrin L, Monroy DC, Selzer M, Lokeshwar B, Pflugfelder SC. Tear fluid gelatinase B activity correlates with IL-1alpha concentration and fluorescein clearance in ocular rosacea. Invest Ophthalmol Vis Sci. 1999;40(11):2506-2512. (Pubitemid 29455477)
8. Brignole F, Pisella PJ, Goldschild M, De Saint Jean M, Goguel A, Baudouin C. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Invest Ophthalmol Vis Sci. 2000;41(6):1356- 1363. (Pubitemid 30261857)
9. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004;137(2):337-342. (Pubitemid 38221009)
10. Ollivier FJ, Gilger BC, Barrie KP, et al. Proteinases of the cornea and preocular tear film. Vet Ophthalmol. 2007;10(4):199-206. (Pubitemid 46906338)
11. Sobrin L, Liu Z, Monroy DC, et al. Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant. Invest Ophthalmol Vis Sci. 2000;41(7):1703-1709. (Pubitemid 30354340)
12. Li DQ, Chen Z, Song XJ, Luo L, Pflugfelder SC. Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2004;45(12):4302-4311. (Pubitemid 39564654)
13. Acera A, Rocha G, Vecino E, Lema I, Durán JA. Inflammatory markers in the tears of patients with ocular surface disease. Ophthalmic Res. 2008;40(6):315-321.
14. Leonardi A, Brun P, Abatangelo G, Plebani M, Secchi AG. Tear levels and activity of matrix metalloproteinase (MMP)-1 and MMP-9 in vernal keratoconjunctivitis. Invest Ophthalmol Vis Sci. 2003;44(7):3052-3058. (Pubitemid 36759772)
15. Lema I, Sobrino T, Durán JA, Brea D, Díez-Feijoo E. Subclinical keratoconus and inflammatory molecules from tears. Br J Ophthalmol. 2009;93(6):820-824.
16. Honda N, Miyai T, Nejima R, et al. Effect of latanoprost on the expression of matrix metalloproteinases and tissue inhibitor of metalloproteinase 1 on the ocular surface. Arch Ophthalmol. 2010;128(4):466-471.
17. Toda I. LASIK and dry eye. Compr Ophthalmol Update. 2007;8(2):79-85. (Pubitemid 46910148)
18. Wilson SE, Stulting RD. Agreement of physician treatment practices with the International Task Force guidelines for diagnosis and treatment of dry eye disease. Cornea. 2007;26(3):284-289. (Pubitemid 46568827)
19. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL, Jacobsen GEA. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118(5):615-621. (Pubitemid 30327337)
20. InflammaDry [package insert]. Sarasota, FL: Rapid Pathogen Screening Inc; 2012.
21. Lemp MA. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J. 1995;21(4):221-232.
22. DogruM, Stern ME, Smith JA, Foulks GN, Lemp MA, Tsubota K. Changing trends in the definition and diagnosis of dry eyes. Am J Ophthalmol. 2005;140(3):507-508.
23. Brewitt H, Sistani F. Dry eye disease: the scale of the problem. Surv Ophthalmol. 2001;45(suppl 2):S199-S202.
24. Vitale S, Goodman LA, Reed GF, Smith JA. Comparison of the NEI-VFQ and OSDI questionnaires in patients with Sjögren's syndrome-related dry eye. Health Qual Life Outcomes. 2004;2:44. doi:10.1186/1477-7525-2-44.
25. Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W. Utility assessment among patients with dry eye disease. Ophthalmology. 2003;110(7):1412-1419. (Pubitemid 36842481)
26. Chalmers RL, Begley CG, Edrington T, et al. The agreement between self-assessment and clinician assessment of dry eye severity. Cornea. 2005;24(7):804-810. (Pubitemid 41400419)
27. Beghi E, Monticelli ML, Amoruso L, Zarrelli MM; Italian General Practitioner Study Group. Prevalence, characteristics, and patterns of health care use for chronic headache in two areas of Italy: results of a questionnaire interview in general practice. Cephalalgia. 2003;23(3):175-182. (Pubitemid 36461385)
28. Kaniecki RG. Migraine and tension-type headache: an assessment of challenges in diagnosis. Neurology. 2002;58(9)(suppl 6):S15-S20. (Pubitemid 34522264)
29. Nelson JD, Farris RL. Sodium hyaluronate and polyvinyl alcohol artificial tear preparations: a comparison in patients with keratoconjunctivitis sicca. Arch Ophthalmol. 1988;106(4):484-487.
30. De Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res. 2006;83(3):526-535. (Pubitemid 43902774)
31. Versura P, Frigato M, Cellini M, Mulè R, Malavolta N, Campos EC. Diagnostic performance of tear function tests in Sjögren's syndrome patients. Eye (Lond). 2007;21(2):229-237. (Pubitemid 46454603)
32. Li M, Du C, Zhu D, Shen M, Cui L, Wang J. Daytime variations of tear osmolarity and tear meniscus volume. Eye Contact Lens. 2012;38(5):282-287.
33. TearLab Performance Testing Summary. 510(k) Summary; Section VI. 2009. http://www.accessdata.fda.gov/cdrh-docs/pdf8/K083184.pdf.AccessedOctober16, 2011.
34. Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol. 2011;151(5):792-798.e1. doi:10.1016/j.ajo.2010.10.032.
35. Pflugfelder SC. Anti-inflammatory therapy of dry eye. Ocul Surf. 2003;1(1):31-36. (Pubitemid 41263855)
36. Foulks GN. Topical cyclosporine for treatment of ocular surface disease. Int Ophthalmol Clin. 2006;46(4):105-122. (Pubitemid 44632214)
37. Gürdal C, Genç I, Saraç O, Gönül I, Takmaz T, Can I. Topical cyclosporine in thyroid orbitopathy-related dry eye: clinical findings, conjunctival epithelial apoptosis, and MMP-9 expression. Curr Eye Res. 2010;35(9):771-777.
38. Djalilian AR, Nagineni CN, Mahesh SP, Smith JA, Nussenblatt RB, Hooks JJ. Inhibition of inflammatory cytokine production in human corneal cells by dexamethasone, but not cyclosporin. Cornea. 2006;25(6):709-714. (Pubitemid 44671862)
39. De Paiva CS, Corrales RM, Villarreal AL, et al. Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. Invest Ophthalmol Vis Sci. 2006;47(7):2847-2856. (Pubitemid 351639757)
40. Akpek EK, Merchant A, Pinar V, Foster CS. Ocular rosacea: patient characteristics and follow-up. Ophthalmology. 1997;104(11):1863-1867. (Pubitemid 28100343)
41. Li DQ, Zhou N, Zhang L, Ma P, Pflugfelder SC. Suppressive effects of azithromycin on zymosan-induced production of proinflammatory mediators by human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2010;51(11):5623-5629.